Inflamm Bowel Dis. 2020 Jun 24;izaa162. doi: 10.1093/ibd/izaa162. Online ahead of print.

Jordan E Axelrad ¹, Lisa Malter ¹, Simon Hong ¹, Shannon Chang ¹, Brian Bosworth ¹, David Hudesman ¹

Author information

• ¹Inflammatory Bowel Disease Center at NYU Langone Health, Division of Gastroenterology and Hepatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY.

Abstract

Background: We aimed to characterize patients with inflammatory bowel disease (IBD) and novel coronavirus disease 2019 (COVID-19).

Methods: We performed a case series of patients with IBD and confirmed or highly suspected COVID-19 to assess rates of severe outcomes.

Results: We identified 83 patients with IBD with confirmed (54%) or highly suspected (46%) COVID-19. The overall hospitalization rate was 6%, generally comprising patients with active Crohn's disease or older men with comorbidities, and 1 patient expired.

Discussion: In this series of patients with IBD, severe outcomes of COVID-19 were rare and comparable to similarly aged individuals in the general population.